# EDGAR Filing Document

**Accession Number:** 0001809616
**File Stem:** 0001213900-23-006011
**Filing Date:** 2023-1
**Character Count:** 5760
**Document Hash:** c2f104337656cd2452fe5e3f40368324
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-006011.hdr.sgml**: 20230130

**ACCESSION NUMBER**: 0001213900-23-006011

**CONFORMED SUBMISSION TYPE**: NT 20-F

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20220930

**FILED AS OF DATE**: 20230130

**DATE AS OF CHANGE**: 20230130

**EFFECTIVENESS DATE**: 20230130

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Universe Pharmaceuticals INC
- **CENTRAL INDEX KEY:** 0001809616
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** F4
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** NT 20-F
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40231
- **FILM NUMBER:** 23567912

**BUSINESS ADDRESS:**
- **STREET 1:** 265 JINGJIU AVENUE
- **STREET 2:** JINGGANGSHAN ECON. AND TECH. DEV. ZONE
- **CITY:** JI'AN, JIANGXI
- **STATE:** F4
- **ZIP:** 343100
- **BUSINESS PHONE:** 86-0796-8403309

**MAIL ADDRESS:**
- **STREET 1:** 265 JINGJIU AVENUE
- **STREET 2:** JINGGANGSHAN ECON. AND TECH. DEV. ZONE
- **CITY:** JI'AN, JIANGXI
- **STATE:** F4
- **ZIP:** 343100

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 12b-25**

**NOTIFICATION OF LATE FILING**

*(Check One)*: ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

---

| | |
|:---|:---|
| For Period Ended: **September 30, 2022** | For Period Ended: **September 30, 2022** |
| ☐ | Transition Report on Form 10-K |
| ☐ | Transition Report on Form 20-F |
| ☐ | Transition Report on Form 11-K |
| ☐ | Transition Report on Form 10-Q |
| For the Transition Period Ended: ___________ | For the Transition Period Ended: ___________ |

---

**Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.**

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I — REGISTRANT INFORMATION**

---

| |
|:---|
| **Universe Pharmaceuticals INC** |
| Full Name of Registrant |
| Former Name if Applicable |
| **265 Jingjiu Avenue, Jinggangshan Economic and Technological Development Zone** |
| Address of Principal Executive Office (Street and Number) |
| **Ji'an, Jiangxi Province, The People's Republic of China 343100** |
| City, State and Zip Code |

---

**PART II — RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The
 reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

☒ (b) The
 subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion
 thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
 of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the
 fifth calendar day following the prescribed date; and

(c) The
 accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

**PART III — NARRATIVE**

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The review of the information required to be presented in the Form 20-F for the fiscal year ended September 30, 2022 has imposed time constraints that have rendered timely filing of the Form 20-F impracticable without undue hardship and expense to the Registrant. Its audit committee of the board of directors and independent registered public accounting firms require additional time to complete their review of the financial statements for the fiscal year ended September 30, 2022. The Registrant anticipates that it will file the Form 20-F no later than the fifteenth calendar day following the prescribed due date.

**PART IV — OTHER INFORMATION**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Name
 and telephone number of person to contact in regard to this notification

<u>Lin Yang, Chief Financial Officer</u> <u>(+86) 571-87555823</u> <br> (Name) (Area Code) (Telephone Number)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Have
 all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
 Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
 been filed? If answer is no, identify report(s).

☒ Yes ☐ No

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) Is
 it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
 reflected by the earnings statements to be included in the subject report or portion thereof?

☐ Yes ☒ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

<u>Universe Pharmaceuticals INC</u>

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: January 30, 2023 |  |  |
|  | By: | /s/ Gang Lai |
|  | Name: | Gang Lai |
|  | Title: | Chief Executive Officer |

---